Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 27 | 2024 | 1260 | 4.050 |
Why?
|
| Drug Resistance, Viral | 25 | 2024 | 278 | 3.970 |
Why?
|
| Anti-HIV Agents | 20 | 2024 | 1324 | 3.060 |
Why?
|
| HIV Infections | 33 | 2024 | 5097 | 2.690 |
Why?
|
| Mutation | 13 | 2024 | 306 | 1.260 |
Why?
|
| Anti-Retroviral Agents | 7 | 2023 | 551 | 1.240 |
Why?
|
| Pyridones | 6 | 2024 | 100 | 1.190 |
Why?
|
| Reverse Transcriptase Inhibitors | 10 | 2024 | 118 | 1.070 |
Why?
|
| Viral Load | 16 | 2023 | 819 | 1.050 |
Why?
|
| Genotype | 14 | 2024 | 442 | 1.000 |
Why?
|
| Humans | 37 | 2024 | 14537 | 0.810 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2022 | 33 | 0.800 |
Why?
|
| HIV Protease Inhibitors | 3 | 2020 | 92 | 0.760 |
Why?
|
| HIV Reverse Transcriptase | 7 | 2024 | 41 | 0.740 |
Why?
|
| Treatment Failure | 11 | 2023 | 175 | 0.710 |
Why?
|
| Sequence Analysis, DNA | 6 | 2016 | 181 | 0.700 |
Why?
|
| Piperazines | 3 | 2023 | 82 | 0.600 |
Why?
|
| Oxazines | 3 | 2023 | 81 | 0.600 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2023 | 85 | 0.600 |
Why?
|
| Retrospective Studies | 5 | 2022 | 799 | 0.520 |
Why?
|
| South Africa | 15 | 2024 | 7596 | 0.490 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2014 | 16 | 0.480 |
Why?
|
| Viremia | 2 | 2021 | 66 | 0.460 |
Why?
|
| Didanosine | 1 | 2014 | 11 | 0.460 |
Why?
|
| Adult | 13 | 2021 | 5913 | 0.440 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 77 | 0.430 |
Why?
|
| Triazoles | 2 | 2024 | 20 | 0.420 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 472 | 0.390 |
Why?
|
| RNA, Viral | 9 | 2022 | 303 | 0.360 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.350 |
Why?
|
| Adolescent | 6 | 2022 | 2985 | 0.340 |
Why?
|
| Tenofovir | 3 | 2022 | 171 | 0.340 |
Why?
|
| Polymerase Chain Reaction | 2 | 2007 | 260 | 0.320 |
Why?
|
| HIV Protease | 2 | 2005 | 22 | 0.320 |
Why?
|
| Child | 5 | 2023 | 2242 | 0.280 |
Why?
|
| Mutation, Missense | 3 | 2016 | 65 | 0.270 |
Why?
|
| Sensitivity and Specificity | 7 | 2022 | 385 | 0.270 |
Why?
|
| DNA, Viral | 1 | 2007 | 165 | 0.270 |
Why?
|
| Male | 10 | 2020 | 6754 | 0.270 |
Why?
|
| Female | 12 | 2020 | 9103 | 0.270 |
Why?
|
| Phylogeny | 3 | 2023 | 231 | 0.260 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1422 | 0.260 |
Why?
|
| Middle Aged | 7 | 2020 | 3601 | 0.260 |
Why?
|
| Young Adult | 6 | 2020 | 2498 | 0.260 |
Why?
|
| Feasibility Studies | 2 | 2021 | 101 | 0.250 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 29 | 0.250 |
Why?
|
| Genotyping Techniques | 2 | 2016 | 38 | 0.250 |
Why?
|
| Thymidine | 1 | 2024 | 6 | 0.240 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2022 | 132 | 0.240 |
Why?
|
| Cohort Studies | 3 | 2021 | 967 | 0.240 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2024 | 198 | 0.220 |
Why?
|
| Rilpivirine | 1 | 2023 | 7 | 0.210 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 23 | 0.200 |
Why?
|
| Zidovudine | 1 | 2022 | 59 | 0.200 |
Why?
|
| Lamivudine | 1 | 2022 | 89 | 0.200 |
Why?
|
| Developing Countries | 2 | 2023 | 400 | 0.190 |
Why?
|
| Drug Resistance | 1 | 2021 | 35 | 0.190 |
Why?
|
| Aged | 2 | 2016 | 1740 | 0.190 |
Why?
|
| Prevalence | 4 | 2020 | 1192 | 0.190 |
Why?
|
| Base Sequence | 2 | 2014 | 149 | 0.180 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 263 | 0.170 |
Why?
|
| World Health Organization | 2 | 2017 | 137 | 0.160 |
Why?
|
| Software | 1 | 2019 | 37 | 0.160 |
Why?
|
| Gene Products, pol | 1 | 2016 | 5 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 217 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 42 | 0.130 |
Why?
|
| Phenotype | 3 | 2024 | 158 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2016 | 120 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 143 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 468 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2019 | 656 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2014 | 56 | 0.120 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2014 | 1 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 8 | 0.120 |
Why?
|
| HIV Core Protein p24 | 1 | 2014 | 18 | 0.120 |
Why?
|
| Virology | 1 | 2014 | 13 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 563 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 38 | 0.120 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 265 | 0.110 |
Why?
|
| Dideoxynucleosides | 1 | 2014 | 29 | 0.110 |
Why?
|
| Viral Tropism | 1 | 2013 | 9 | 0.110 |
Why?
|
| Stavudine | 1 | 2014 | 78 | 0.110 |
Why?
|
| Plasma | 2 | 2013 | 39 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 91 | 0.110 |
Why?
|
| Lopinavir | 2 | 2020 | 137 | 0.080 |
Why?
|
| Ritonavir | 2 | 2020 | 137 | 0.080 |
Why?
|
| Succinates | 1 | 2009 | 3 | 0.080 |
Why?
|
| Triterpenes | 1 | 2009 | 2 | 0.080 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 20 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 99 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2007 | 17 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2018 | 353 | 0.070 |
Why?
|
| Genes, Viral | 1 | 2005 | 11 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2005 | 35 | 0.060 |
Why?
|
| Deoxyadenosines | 1 | 2024 | 2 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2009 | 529 | 0.060 |
Why?
|
| Integrases | 1 | 2023 | 2 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2018 | 1160 | 0.060 |
Why?
|
| Malawi | 1 | 2023 | 87 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 47 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2023 | 889 | 0.050 |
Why?
|
| Namibia | 1 | 2020 | 19 | 0.040 |
Why?
|
| DNA Primers | 2 | 2013 | 55 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 64 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 296 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 44 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2018 | 133 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 279 | 0.040 |
Why?
|
| Public Sector | 1 | 2019 | 82 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 151 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2018 | 480 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 45 | 0.030 |
Why?
|
| Biosensing Techniques | 1 | 2014 | 6 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 27 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 91 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2014 | 53 | 0.030 |
Why?
|
| Dried Blood Spot Testing | 1 | 2014 | 24 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2014 | 120 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2013 | 12 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2014 | 105 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 56 | 0.030 |
Why?
|
| Africa | 1 | 2013 | 376 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2014 | 336 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1748 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 2014 | 299 | 0.020 |
Why?
|
| Burkina Faso | 1 | 2009 | 29 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 31 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 14 | 0.020 |
Why?
|
| Kenya | 1 | 2009 | 183 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 59 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 40 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 139 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 2005 | 1 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 17 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2005 | 11 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 1862 | 0.010 |
Why?
|